

Minutes of the **Somerset Prescribing Forum** held via Microsoft Teams, on **Wednesday, 11th May 2022**.

Present:	Dr Clare Barlow (CB)	Chair D&TC, Somerset NHSFT
	Steve DuBois (SDB)	Chief Pharmacist, Somerset NHSFT
	Shaun Green (SG)	Deputy Director of Clinical Effectiveness and Medicines Management, CCG
	Sam Morris (SM)	Medicines Manager, CCG
	Andrew Prowse (AP)	Chief Pharmacist and Controlled Drugs Accountable Officer, YDH NHS FT
	Dr Carla Robinson (CR)	Public Health Registrar, Somerset County Council
	Caroline Taylor (CT)	Prescribing Technician, CCG
Apologies:	Jean Perry (JP)	Contracts Manager, NHS Somerset CCG
	Dr Andrew Tresidder (AT)	Chair, CCG GP Patient Safety Lead

1 APOLOGIES FOR ABSENCE AND INTRODUCTIONS

Apologies were provided as detailed above.

2 REGISTER OF MEMBERS' INTERESTS

- 2.1 The Somerset Prescribing Forum received the Register of Members' Interests relevant to its membership.

There were no further amendments to the Register.

The Somerset Prescribing Forum noted the Register of Members' Interests.

3 DECLARATIONS OF INTEREST RELATING TO ITEMS ON THE AGENDA

- 3.1 Under the CCG's arrangements for managing conflicts of interest, any member making a declaration of interest is able to participate in the discussion of the particular agenda item concerned, where appropriate, but is excluded from the decision-making and voting process if a vote is required. In these circumstances, there must be confirmation that the meeting remains quorate in order for voting to proceed. If a conflict of interest is declared by the Chairman, the agenda item in question would be chaired by a nominated member of the Somerset Prescribing Forum.

There were no declarations of interest relating to items on the agenda.

4 MINUTES OF THE MEETING HELD ON 16th March 2022

4.1 The Minutes of the meeting held on 16th March were agreed as a correct record.

4.2 **Review of action points**

Most items were either complete or, on the agenda.

Action 2: YDH Formulary proposal: Ozudex for Phakic DMO

After gaining virtual approval, approved for use by SPF as **RED**

Action: ZTW Add to TLS as RED

5 **Matters Arising**

-Nothing to raise

6 **Other Issues for Discussion**

6.1 **Continuous Glucose Monitoring - CGM**

See Formulary Application Agenda item 9.3

-Noted

7 **Other Issues for Noting**

7.1 **Increase in hepatitis (liver inflammation) cases in children under investigation**

-Noted

Awareness raised with primary care.

8 **Additional Communications for Noting**

These are items shared by the MMT with primary care colleagues, which may be of interest for trusts and the wider system.

8.1 **Personally administered items - practice or contractor stock advice**

-Noted

Reiterated the legal guidance around issuing FP10 for care homes and primary care stocks.

8.2 **Updated IIF incentives**

Preventative items, focus on addressing unmet need. Carbon-footprint and sustainability should be incorporated in SMRs.

Between 10-15% of emergency admissions maybe medicines related.

Patients with familial hypercholesteremia, need to be referred to a lipid specialist. A business plan has been put forward highlighting the gap in Somerset for this service.

-Noted

8.3 **2022-23 prescribing and quality improvement scheme**

The purpose of the scheme is to improve patient outcomes.

Revision of the Indicator targets has been carried out with a few changes & amendments.

-Noted

8.4 **Potential sepsis patients and Ambulance waits**

Highlighted recent incident, concerned (primary care) GP administered I.V antibiotics appropriately.

-Noted

8.5 **AF & Stroke**

Addressing unmet need.

-Noted

8.6 **Guidance on prescription duration**

Reiterating details of supply, duration, synchronisation.

-Noted

8.7 **Removal of Diprobase cream (May) and ointment (June) from drug tariff**

-Noted

9 **Formulary Applications**

9.1 **Sereflo Ciphaler 50mcg salmeterol / 250 mcg fluticasone, Cipla EU Ltd 1 x 60 dose =£33.95**

Approved by PAMM at April's meeting.

Approved by SPF

Add to Venn diagram.

Add to formulary.

Action: Caroline Taylor

Action: EK

9.2 **Actimorph, Orodispersible morphine SF tabs, Ethypharm UK Ltd**

1mg x 56 =£2.00, 2.5mg x 56 =£2.50, 5mg x 56 =£3.50, 10mg x 56 =£4.75
20mg x 56 =£9.50, 30mg x 56 =£13.00

Cost effective, will assist with stepping down dosages. Alternative to morphine solution for patients needing breakthrough pain relief, only when necessary. Advantageous over liquid oral morphine as both alcohol & sugar free. Also, no sodium content.

AP highlighted, Actimorph® is a Schedule 2 CD, Oramorph® is Schedule 5. SM highlighted that the CD classification for Oramorph® is being revised.

Advice in switching patients must be carried out face to face. This ensures discussions take place and give clarification on the dose the patient is actually taking.

Approved by PAMM at April's meeting.

SPF Approved

-Noted

9.3 **GlucoRx AiDEX Sensor, GlucoRx Ltd, 1 Sensor £29.95**

Cost effective option

PAMM, at its meeting in May, approved extended access to prescribable rtCGM (currently GlucoRx Aidex) or isCGM (Freestyle libre2) for ALL Type 1 patients (without exception).

PAMM will review guidance for Type 2 prescribed insulin at its June meeting.

For other rtCGM not in the drug tariff so not available for GP prescribing a new Criteria Based Access (CBA) policy will apply from Mid-June

Accept GlucoRx AiDEX Sensor onto CCG formulary for Type1 patients

-Noted

10 **DTC decisions and other reports**

10.1 **Somerset NHS Foundation Trust Mental Health D&TC** - Last meeting 08/03/22 Minutes not received – verbal update given

10.2 **YDH Medicines Committee** - last meeting 18/ 03/2022

Verbal update from AP & SM

- YDH contacted patients affect by the Alimentum and Elecare recall
- Ozudex discussed
- Minor updates to many PGDs
- Audit of errors and missed doses on discharge summary. 10,000 errors per year.
- Request for Ferric maltol to be added to formulary had not followed due process so likely to come to us in the next few months.

10.3 **Somerset NHSFT D&TC** - Next meeting 13/05/22

10.4 **Somerset Antimicrobial Stewardship Committee** - Next meeting TBC

10.5 **Somerset ICS Medicines Optimisation (SIMO) Committee** - Last meeting 16/02/2022 draft Minutes received

Verbal update:

- Electronic Prescribing and Medicines Administration (EPMA) delays
- Discharge medicines service
- Workstream infographic shared with team
- Implementing Community Pharmacy Clinical Services
- GP Community Pharmacy referral system - prevents hospitalising patients

10.6 **Regional Medicines Optimisation Committee (Southwest)** - Next meeting 08/06/2022

Part 2 – Items for Information or Noting

11 **NICE Guidance March & April**

-Noted

12 NICE Technology Appraisals

- 12.1 **[TA779] Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency** - New within the Cancer Drugs Fund
-Approved
NHSE Commissioned. Add to TLS **RED** Drug Action: ZTW
- 12.2 **[TA780] Nivolumab with ipilimumab for untreated advanced renal cell carcinoma** - New
-Approved
NHSE Commissioned. Add to TLS **RED** Drug Action: ZTW
- 12.3 **[TA782] Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm (terminated appraisal)**
-Noted
- 12.4 **[TA781] Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer** -New within the Cancer Drugs Fund
-Approved
NHSE Commissioned. Add to TLS **RED** Drug Action: ZTW
- 12.5 **[TA783] Daratumumab monotherapy for treating relapsed and refractory multiple myeloma** - New
-Approved
NHSE Commissioned. Add to TLS **RED** Drug Action: ZTW
- 12.6 **[TA785] Nivolumab with cabozantinib for untreated advanced renal cell carcinoma (terminated appraisal)**
- 12.7 **[TA784] Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer** - New
-Approved
NHSE Commissioned. Add to TLS **RED** Action:
ZTW
- 12.8 **[TA787] Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable** -New
-Approved
NHSE Commissioned. Add to TLS **RED** Action: ZTW

- 12.9 **[TA786] Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies** - New
 -Approved
NHSE Commissioned. Add to TLS RED **Action: ZTW**
- 13 NICE Clinical Guidance**
- 13.1 **[NG214] Integrated health and social care for people experiencing homelessness** -New
 CR passed on to work colleagues for information.
 Raise concern of patients struggling to register at GP practices
 -Noted
- 13.2 **[NG136] Hypertension in adults: diagnosis and management** - Update
 Published: August 2019 Last updated: March 2022
 -Noted
Update formulary **Action: EK**
- 13.3 **[NG191] COVID-19 rapid guideline: managing COVID-19** -Update
 -Noted
- 13.4 **[NG28] Type 2 diabetes in adults: management** - Update
 -Noted
 Lesley Harper is the Programme Lead Officer for the Somerset low-calorie diabetes programme.
- 13.5 **[NG18] Diabetes (type 1 and type 2) in children and young people: diagnosis and management** - Update
 -Noted
- 13.6 **[NG17] Type 1 diabetes in adults: diagnosis and management** -Update
 -Noted
- 13.7 **[NG128] Stroke and transient ischaemic attack in over 16s: diagnosis and initial management** -Update
 -Noted
- 13.8 **[NG215] Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults** - New

NICE have produced visual summaries for 'before starting' & 'reviewing' these medicines.

Patients need to be given information, set expectations, explaining the risks, harms, and perceived benefits.

Pregnant patients' management plan.

Somerset CCG website contains lots of useful & helpful resources.

-Noted

13.9 **[NG217] Epilepsies in children, young people and adults** -New

Highlighted to trusts for review.

-Noted

14 Specialist Commissioning

SG was not present at this point in the meeting.

Agreed to bring back to July meeting

15 Risk review and management

15.1 **Risk review and Management - COVID 19**

-Nothing to note

16 Safety Items, NPSA Alerts and Signals

16.1 **MHRA Drug Safety Update March & April**

-Noted

16.2 **Cladribine (Mavenclad): new advice to minimise risk of serious liver injury**

-Noted

16.3 **Amiodarone (Cordarone X): reminder of risks of treatment and need for patient monitoring and supervision**

Eclipse Live have safety searches to identify primary care patients.

-Noted

16.4 **Metformin in pregnancy: study shows no safety concerns**

Positive & useful study.

-Noted

16.5 **Pregabalin (Lyrica): findings of safety study on risks during pregnancy.**

Pregabalin should NOT be used in first trimester unless full risk benefit analysis conducted

Patients should receive a pre-pregnancy conversation with GP, (folic acid needs as well as suitability for ongoing treatment, or alternative options) SDB highlighted, SomersetFT Mental Health team are compiling a register of patients on the mental health register.

SM is looking at drugs that are safe / suitable during pregnancy as well as lactation.

-Noted

16.6 **NIHR alerts:**

Almost half those on long-term antidepressants can stop without relapsing - Informative and accessible health and care research

Better access to talking therapies

-Noted

16.7 **NIHR alerts:**

People of all ages benefit from drugs to lower blood pressure

Excluding a cohort of elderly patients, who may experience dizziness causing falls.

-Noted

17 **High-Cost Drugs**

PBR excluded High-cost drugs budgets

-Noted

18 **Any Other Business**

18.1 -None

DATE OF NEXT MEETING

13th July

MEETING DATES FOR 2022

14th September

16th November